# Pizarra — PT-pseudo_d38917f87b35 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d38917f87b35
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 28.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: -0.78 ng/mL/yr
  - Prior PSA: 25.3 ng/mL
  - Prostate volume: 70.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8709831 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia
  - Current medication: empagliflozin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.

Vitals: weight 99 kg, height 177 cm, BMI 31.6, BP 126/68 mmHg, HR 67 bpm. Smoking: Ex-smoker (23 pack-yr, quit 2015).

Chief complaint: Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review.

History: A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine.

Physical examination: DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable.

Patient info: retired firefighter; Widowed; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 12 units / week; exercise Running 3x/week, 5 km; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.25 +/- 0.11   (95% CI 0.05-0.46)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.11  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.82 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or further action. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context of the PI-RADS 5 score, the rising PSA velocity (-0.78 ng/mL/yr), and the prior positive biopsy result. It did not account for the specific clinical dilemma of a patient with a known prior malignancy being re-evaluated.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.25, which is a 'firm' prior. This suggestion could be wrong because the prior failed to recognize that a PI-RADS 5 score combined with a rising PSA velocity and a prior positive biopsy suggests a high-risk scenario that overrides the baseline statistical prediction. The high aleatoric uncertainty (H=0.82) indicates the model struggles with this specific clinical intersection, suggesting the model's suggestion is highly sensitive to the data distribution it was trained on.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value?
3. previous_notes - What was the prior grade, surveillance pathway, and management agreement?
4. laboratory panel - (Dropped by Moderator, but if retrieved, it might clarify baseline PSA density/other labs).

Retrieving the radiology report is critical to determine if the PI-RADS 5 lesion has changed, which directly impacts the need for a repeat biopsy.

GUIDELINE ANCHOR
Guidelines suggest that a stable MRI (PRECISE 1-3) combined with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy, but the presence of a PI-RADS 5 lesion warrants further investigation.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Left peripheral zone mass scoring PI-RADS 5. Lesion measures roughly 28 mm. Shows prompt, localized enhancement and marked diffusion restriction. Estimated csPCa probability computes to 0.8709831.
get_psa_trend
PSA trend: Shows a significant rising trajectory from 1.3 ng/mL (Jul 2023) to 28.3 ng/mL (Jan 2025).
get_previous_notes
Previous notes: Prior biopsy confirmed ISUP GG5 disease. Patient was under clinical tracking for LUTS progression and general health. No explicit mention of a surveillance protocol or agreed-upon re-biopsy plan in the retrieved notes.

NOT RETRIEVED
laboratory_results
Laboratory results were deliberately left closed because the moderator's agenda did not explicitly require them, and retrieving them would not change the immediate decision path based on the other retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 score and a measurable lesion (28 mm) are present, indicating high suspicion for clinically significant cancer.
- PSA trend: Significant rising trend from 1.3 ng/mL to 28.3 ng/mL over approximately 1 year.
- Previous notes: Prior biopsy confirmed ISUP GG5 disease, and no explicit surveillance protocol or re-biopsy plan was documented.

AGAINST sampling this patient now:
- Previous notes: No explicit documentation of an active surveillance protocol or agreed-upon re-biopsy plan.

WHERE THIS LEANS
The combined evidence of a high-risk MRI finding (PI-RADS 5), a rapidly rising PSA trend, and the lack of a documented surveillance plan strongly supports proceeding with a re-biopsy to characterize the lesion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 5 MRI, significant PSA rise, and lack of surveillance plan) strongly supports proceeding with a re-biopsy.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context of the PI-RADS 5 score, the rising PSA velocity (-0.78 ng/mL/yr), and the prior positive biopsy result. It did not account for the specific clinical dilemma of a patient with a known prior malignancy being re-evaluated.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.25, which is a 'firm' prior. This suggestion could be wrong because the prior failed to recognize that a PI-RADS 5 score combined with a rising PSA velocity and a prior positive biopsy suggests a high-risk scenario that overrides the baseline statistical prediction. The high aleatoric uncertainty (H=0.82) indicates the model struggles with this specific clinical intersection, suggesting the model's suggestion is highly sensitive to the data distribution it was trained on.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
2. psa_trend - What is the serial PSA trend beyond the headline value?
3. previous_notes - What was the prior grade, surveillance pathway, and management agreement?
4. laboratory panel - (Dropped by Moderator, but if retrieved, it might clarify baseline PSA density/other labs).

GUIDELINE ANCHOR
Guidelines suggest that a stable MRI (PRECISE 1-3) combined with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy, but the presence of a PI-RADS 5 lesion warrants further investigation.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Left peripheral zone mass scoring PI-RADS 5. Lesion measures roughly 28 mm. Shows prompt, localized enhancement and marked diffusion restriction. Estimated csPCa probability computes to 0.8709831.
get_psa_trend
PSA trend: Shows a significant rising trajectory from 1.3 ng/mL (Jul 2023) to 28.3 ng/mL (Jan 2025).
get_previous_notes
Previous notes: Prior biopsy confirmed ISUP GG5 disease. Patient was under clinical tracking for LUTS progression and general health. No explicit mention of a surveillance protocol or agreed-upon re-biopsy plan in the retrieved notes.

NOT RETRIEVED
laboratory_results
Laboratory results were deliberately left closed because the moderator's agenda did not explicitly require them, and retrieving them would not change the immediate decision path based on the other retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 score and a measurable lesion (28 mm) are present, indicating high suspicion for clinically significant cancer.
- PSA trend: Significant rising trend from 1.3 ng/mL to 28.3 ng/mL over approximately 1 year.
- Previous notes: Prior biopsy confirmed ISUP GG5 disease, and no explicit surveillance protocol or re-biopsy plan was documented.

AGAINST sampling this patient now:
- Previous notes: No explicit documentation of an active surveillance protocol or agreed-upon re-biopsy plan.

WHERE THIS LEANS
The combined evidence of a high-risk MRI finding (PI-RADS 5), a rapidly rising PSA trend, and the lack of a documented surveillance plan strongly supports proceeding with a re-biopsy to characterize the lesion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fully addressed by retrieving the MRI report, PSA trend, and previous notes. The evidence strongly leans towards biopsy, despite the disagreement between the statistical prior (No Biopsy) and the evidence (Biopsy).

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

The statistical prior suggested no biopsy (p=0.25), which was overturned by the retrieved evidence supporting biopsy. The evidence included a PI-RADS 5 score and a significant PSA trend from 1.3 ng/mL to 28.3 ng/mL, combined with the lack of a documented surveillance plan. The guideline criterion abstained because the panel was inconclusive, leaving the decision to the retrieved documents. Therefore, the split between the prior and the evidence results in a borderline confidence level.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
